Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Plasma cell 1 Other hematologic neoplasm 1 Lymphoid 1 Gastrointestinal 1 Dermatologic 1

Conditions

Interventions

Ipilimumab 101 pembrolizumab 94 Nivolumab 87 Cyclophosphamide 69 fludarabine phosphate 55 aldesleukin 52 Interleukin-2 39 Dacarbazine 35 Vemurafenib 31 fludarabine 30 trametinib 29 dabrafenib 29 Temozolomide 28 Whole-Body Irradiation 21 Aminolevulinic Acid 21 Carboplatin 20 CTLA-4 Antigen 20 Bevacizumab 20 Radiotherapy 19 Peripheral Blood Stem Cell Transplantation 19 Radiosurgery 18 Tacrolimus 17 Mycophenolic Acid 17 Paclitaxel 16 HhAntag691 16 3-ingenyl angelate 16 Busulfan 15 Introns 14 Antilymphocyte Serum 14 encorafenib 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Anti-Bacterial Agents × Dermatologic × Clear all

NCT03817125 2024-06-06

MCGRAW

Parker Institute for Cancer Immunotherapy

Phase 1 Completed

14 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡